Clostridium difficile Polypeptides for Vaccine Immunogenicity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Clostridium difficile infections, including antibiotics and toxoid vaccines, are inadequate in preventing colonization and recurrence due to resistance issues and limited ability to eliminate spores, necessitating the development of improved polypeptides for vaccine components that can effectively raise immune responses.

Innovation Solution

Identification and use of specific polypeptides derived from Clostridium difficile, such as Dif44 and Dif208, which are immunogenic and capable of reducing gut colonization, incorporated into vaccine compositions to provide protective effects against C. difficile infections.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If toxoid vaccines are used to treat C. difficile infection, then toxin binding is prevented and inflammatory effects are neutralised, but colonization cannot be completely prevented and spores remain in the body

Engineering Contradiction:

Improvetoxin binding and inflammatory effectsVSAvoidprevention of colonization and elimination of spores

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The vaccine is segmented into multiple components: a toxoid component (inactivated toxin) and additional immunogenic components from C. difficile (such as surface proteins, cell wall components, or other virulence factors). This segmentation allows the vaccine to target multiple aspects of the infection simultaneously - neutralizing toxins while also inducing immunity against colonization and spore formation.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The vaccine uses a composite antigen composition combining processed toxin (toxoid) with other C. difficile derived components. This composite approach creates a multi-functional immunogen that can elicit both neutralizing antibodies against toxins and protective immunity against colonization, addressing the limitations of single-component toxoid vaccines.

Inventive Principle:

Principle #40Composite materials

2Object-generated harmful factors

If antibiotics are used to treat C. difficile infection, then bacterial growth is inhibited, but resistance develops over time and gut flora balance is further disrupted

Engineering Contradiction:

Improvebacterial growthVSAvoidresistance development and gut flora balance

Core Design Contradiction:

Object-generated harmful factorsVSAdaptability or versatility

Solution Approach 1:

The vaccine converts the harmful toxins produced by C. difficile into a beneficial therapeutic agent by using processed toxin (toxoid) as the primary immunogen. The toxic protein is inactivated through processing (heat, chemical treatment, or enzymatic degradation) to eliminate its harmful effects while retaining its immunogenicity, allowing it to stimulate protective immune responses without causing damage.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The vaccine acts as an intermediary approach between antibiotics and natural immunity. Rather than directly killing bacteria (antibiotics) or relying solely on the host's unaided immune system, the vaccine provides trained immunity by pre-exposing the immune system to controlled amounts of C. difficile antigens, enabling the body to mount an effective response against actual infection without the side effects of antibiotics.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If repeated vaccine administrations are given to elicit immune response, then protection against toxin binding is improved, but injection site immune reactions occur and administration complexity increases

Engineering Contradiction:

Improveimmune response against toxinVSAvoidadministration frequency and injection site reactions

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The vaccine modifies key parameters of the immunogen to enhance immunogenicity and reduce reactogenicity. The toxin is processed (chemically or physically modified) to change its properties - reducing its ability to bind to host cells while maintaining or enhancing its ability to stimulate immune responses. This parameter change allows for reduced dosing frequency and fewer injection site reactions.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The vaccine uses processed toxin copies rather than full-length active toxin. The toxin protein is fragmented, denatured, or chemically modified to create immunogenic copies that retain protective epitopes but lack full pathogenicity. This copying approach allows the immune system to recognize and respond to the pathogen without being exposed to the complete harmful effects of the native toxin.

Inventive Principle:

Principle #26Copying

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The use of these polypeptides significantly reduces C. difficile colonization and spore-induced disease relapse, offering a more effective prevention and treatment approach compared to existing methods by eliciting a protective immune response.

Implementation Method 1

particularly polypeptides which are immunogenic and suitable for use in immunogenic compositions, for instance vaccine compositions

Methodology Applied

Scientific EffectImmunogenicity:

Data Source

PatentUS9932374B2Clostridium difficile polypeptides as vaccine

Publication Date: 2018.04.03 GLAXOSMITHKLINE BIOLOGICALS SA

AI summary

The invention provides methods, proteins, nucleic acids and antibodies for preventing or treating a C. difficile infection in a mammal.